Dr. Charles S. Carignan is currently the Executive Chairman of Cairdac, and a Director of Biothea Pharma and Prothea. He is an advisor to several Biotech and MedTech companies. He previously served as the CEO of SoniVie, Executive Chair and CEO of Rex Bionics, as the President and CEO of BionX Medical Technology (sold to Ottobock), founding President and CEO of NinePoint Medical, Executive Vice President and Chief Medical Officer of Novasys Medical, Inc. (sold to Roper), Chief Medical Officer at Boston Scientific, and Vice President of clinical research and medical affairs at Conceptus (sold to Bayer).

He received a BA from Yale University and an MD from the College of Physicians and Surgeons, Columbia University. He trained in general surgery at Columbia-Presbyterian Medical Center.

He has served healthcare worldwide participating on committees of the U.S. Food and Drug Administration, Centers for Medicare Camp; Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development.

Henry L. Charlton is senior vice president and chief commercial and marketing officer at Intuitive, leading end-to-end customer engagement globally. Previously he was senior vice president and general manager for the U.S. and E.U. regions at Intuitive. Since joining Intuitive in 2003, he has held leadership positions including: chief commercial officer, senior vice president of U.S. sales; vice president of sales, marketing and training in Europe, the Middle East, India, and Africa (EMEIA) and Latin America, Canada and Australia (LACA); vice president, U.S. key accounts, and a variety of other leadership roles.

Before joining Intuitive, Charlton was at Tidal Software (acquired by Cisco) serving as vice president of Eastern U.S. Sales. He also worked at Securant Technologies (acquired by RSA Securities), Legato Systems (acquired by EMC), and U.S. Surgical Corporation (acquired by Tyco).

Charlton earned his BA in history and english from the University of Pittsburgh.

From 1981 until 2013, Fabrizio Landi was co-founder and then part of the Executive Management of Esaote, where he held various positions (up to CEO and General Manager). He is currently a Board Member of Menarini Diagnostics, Firma and Silicon Biosystem (Menarini Group). He was also a board member of several Italian and international corporates, including Bracco US, Banca CR of Florence (part of Banca Intesa Group) and Leonardo-Finmeccanica. Since 2014 he is Chairman of Toscana Life Sciences TLS Foundation in Siena, supporting many biomedical and biopharmaceutical start-ups and no-profit and for-profit pharma and biotech research groups. He holds several positions in various Scientific Committees and is also actively involved in Fondazione R&I, focused on supporting Technology Transfer processes in Italy.

Graduated with a degree in bioengineering at the Milan Polytechnic, Fabrizio has a long career in the Life Science sector, started with Bayer in 1979.

In 2015, he co-founded Panakes Partners SGR, an investment company focused on Life Sciences Venture Capital activities: at Panakès, he is currently a Managing Partner of the first Fund, dedicated to Medtech and healthcare IT, investing all over Europe since 2016.

Before joining Turenne Capital as Investment Director Healthcare in July 2022, Claire worked for 7 years in the Omnes Capital VC Healthcare team. She began her career in research at the Singapore Institute for Neurotechnology. Claire Poulard holds a master’s degree in Pharmaceutical Management and Biotechnology from ESCP Europe and a master in Bioengineering and Neuroscience Innovation from ESPCI (Ecole Supérieure de Physique et Chimie Industrielle).

Amine Benmoussa is a Partner at Karista and leads the firm’s Benelux office. Karista is a leading pan-European venture capital firm headquartered in Paris.

Amine brings over 15 years of experience in HealthTech venture investing across North America and Europe. Before joining Karista, Amine was an investor with the BDC Healthcare Fund in Canada, where he led or co-led investments in early- to mid-stage HealthTech companies and served on several boards, including Circle Cardiovascular Imaging (acquired by Thoma Bravo), Clearwater Clinical (acquired by Sivantos), Clementia Pharmaceuticals (IPO and later acquired by Ipsen), Milestone Pharmaceuticals (IPO), and Swift Medical.

Amine holds a Bachelor’s degree in Computer Science from Concordia University and an MBA from HEC Montréal. He has also completed executive training in Private Equity and Venture Capital at Harvard Business School and in Corporate Governance at the Rotman School of Management.

Olivier is CEO of SamanTree Medical, which has developed and commercializes the Histolog Scanner for fresh tissue analysis during cancer surgery or cancer diagnostics biopsies.

Prior to SamanTree Medical, Olivier was CEO of Miracor Medical for 7 years, SVP Commercial at PneumRx for 3 years (acquired by BTG in 2015) and VP Commercial at Tryton Medical for 5 years. Olivier started his medtech career in management positions at Guidant and Abbott.

Olivier is also a Venture Partner with SPRIG Equity, a US Venture Capital fund dedicated to best-in-class teams and medical technologies at growth equity and late-stage venture.

Olivier is a director of Miracor Medical (coronary sinus occlusion & Left ventricular Assist intervention devices), Endotools Therapeutics (Endoscopic Sleeve Gastroplasty) and Intressa Vascular (aortic dissections).

Olivier earned a Masters Degree in Business from the UCL, Belgium, and an M.B.A. from the University of Chicago.